ScinoPharm Taiwan (1789.TW) Earnings Analysis

ScinoPharm Taiwan (1789.TW) next reports earnings on 2026-08-12. Last quarter (2026-03-04) it missed with EPS 0.049 TWD vs 0.13 TWD est (-62.3%). It has beaten estimates in 2/5 recent quarters (40%). Trailing P/E 154.09.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does 1789.TW next report earnings?

Next earnings date2026-08-12
Consensus EPS estimaten/a
Revenue estimaten/a

1789.TW earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-03-040.049 TWD0.13 TWD-62.3%Miss
2025-11-030.01952 TWD0.1 TWD-80.5%Miss
2025-05-050.06 TWD0.04 TWD+50%Beat
2024-11-040.03422 TWD0.08 TWD-57.2%Miss
2024-08-050.09459 TWD0.08 TWD+18.2%Beat

Beat rate: 2/5 (40%) over reported quarters with consensus data.

1789.TW valuation and analyst view

Trailing P/E154.09
Trailing EPS0.13002 TWD
Price / book1.59
Dividend yield1.46%
Market cap15.62B

Limited or no published sell-side analyst coverage for this symbol.

Related research pages

Frequently asked questions

When is ScinoPharm Taiwan (1789.TW)'s next earnings date?

ScinoPharm Taiwan is next scheduled to report on 2026-08-12.

Did 1789.TW beat earnings last quarter?

In its 2026-03-04 report, 1789.TW posted EPS of 0.049 TWD versus a 0.13 TWD estimate — a miss of 62.3%.

What is 1789.TW's earnings track record?

Over the last 5 reported quarters with consensus data, 1789.TW beat estimates 2 times (40%).

What is 1789.TW's current P/E ratio and EPS?

1789.TW trades at a trailing P/E of 154.09 on trailing EPS of 0.13002238489926796 TWD.

What do analysts rate 1789.TW?

1789.TW has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.